Ultrasound-guided Brachytherapy for Cervix Cancer

Dyk, Sylvia van; Khaw, Pearly; Lin, Ming Yin; Chang, David; Bernshaw, David

doi:10.1016/j.clon.2021.02.011

Cited by 16 publications

(14 citation statements)

References 43 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ultrasound in medicine was firstly developed by the military (as "sonar") and was firstly investigated in the 1940s by the method of echo-reflection to detect tumors, exudates, or abscesses [31]. Ultrasound developed very much in obstetrics and gynecology to evaluate the growing fetus and examinations in gynecological conditions [32].…”

Section: Clinical Results Of Ultrasound In Brachytherapy For Cervical Cancermentioning

confidence: 99%

“…However, TAUS still has some limitations in patients who cannot have a full bladder (cystostomy or vesicovaginal fistula), and the concept of TAUS in adaptive treatment is still on point-based planning (e.g., cervix reference points). The concept of volume-based approaches via 3D ultrasound is pending [31]. However, TAUS is inexpensive, portable, non-ionizing, and real-time equipment.…”

Section: Experiences Of Taus-guided Brachytherapy In the Division Of Radiation Oncology Department Of Radiology Faculty Of Medicine Chianmentioning

confidence: 99%

See 1 more Smart Citation

Ultrasound-Guided Brachytherapy for Cervical Cancer - A Tool for Quality Improvement in Brachytherapy?

Tharavichitkul¹,

Galalae²

2022

Radiation Oncology

View full text Add to dashboard Cite

Nowadays, brachytherapy is one of the major components to treat inoperable cervical cancer. Brachytherapy yields a higher dose to the target (cervix) while sparing normal tissues. Developments of brachytherapy stepped forward in the previous decade by image-guided brachytherapy (IGBT) turning brachytherapy from point-based planning to volume-based planning and IGBT improves the treatment quality for cervical cancer. Magnetic resonance imaging (MRI) or computed tomography (CT) is utilized in brachytherapy and showed promising results internationally. However, in a limited-resource area, the implementation of IGABT is difficult due to many causes (manpower, equipment, or budgets). To improve the quality in limited resources, ultrasound is introduced. The utilization of ultrasound in brachytherapy practice is to prevent uterine perforation during application. With present data, measurement by ultrasound showed the correlation to MRI measurement in uterine dimensions. With these aspects, there are many researches using ultrasound to improve the quality of treatment in brachytherapy, for example, to guide contouring on CT or to support brachytherapy planning. The use of ultrasound improves the quality of brachytherapy in comparison to conventional planning and supports the improvement in brachytherapy for cervical cancer.

show abstract

Section: Clinical Results Of Ultrasound In Brachytherapy For Cervical Cancermentioning

confidence: 99%

Section: Experiences Of Taus-guided Brachytherapy In the Division Of Radiation Oncology Department Of Radiology Faculty Of Medicine Chianmentioning

confidence: 99%

Ultrasound-Guided Brachytherapy for Cervical Cancer - A Tool for Quality Improvement in Brachytherapy?

Tharavichitkul¹,

Galalae²

2022

Radiation Oncology

View full text Add to dashboard Cite

show abstract

“…Increasing the distribution and absorption of chemotherapy drugs through the use of ultrasonic contrast agents (UCAs) as carriers is essential for improving the chemotherapy efcacy of tumor patients [12]. Advanced cervical cancer is treated with brachytherapy, and using ultrasonography during brachytherapy signifcantly improves the prognosis for cervical cancer patients [14]. Additionally, ultrasound combined with micro/nanobubbles can transfer genes and antigens to cells, which may efectively increase the response of tumors to immunotherapy [15].…”

Section: Introductionmentioning

confidence: 99%

Identification of Ultrasound-Sensitive Prognostic Markers of LAML and Construction of Prognostic Risk Model Based on WGCNA

Tian¹,

Guo

Wei³

2023

Journal of Oncology

View full text Add to dashboard Cite

Background. Acute myeloid leukemia (LAML) is the most widely known acute leukemia in adults. Chemotherapy is the main treatment method, but eventually many individuals who have achieved remission relapse, the disease will ultimately transform into refractory leukemia. Therefore, for the improvement of the clinical outcome of patients, it is crucial to identify novel prognostic markers. Methods. The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases were utilized to retrieve RNA-Seq information and clinical follow-up details for patients with acute myeloid leukemia, respectively, whereas samples that received or did not receive ultrasound treatment were analyzed using differential expression analysis. For consistent clustering analysis, the ConsensusClusterPlus package was utilized, while by utilizing weighted correlation network analysis (WGCNA), important modules were found and the generation of the coexpression network of hub gene was generated using Cytoscape. CIBERSORT, ESTIMATE, and xCell algorithms of the “IOBR” R package were employed for the calculation of the relative quantity of immune infiltrating cells, whereas the mutation frequency of cells was estimated by means of the “maftools” R package. The pathway enrichment score was calculated using the single sample Gene Set Enrichment Analysis (ssGSEA) algorithm of the “Gene Set Variation Analysis (GSVA)” R package. The IC50 value of the drug was predicted by utilizing the “pRRophetic.” The indications linked with prognosis were selected by means of the least absolute shrinkage and selection operator (Lasso) Cox analysis. Results. Two categories of samples were created as follows: Cluster 1 and Cluster 2 depending on the differential gene consistent clustering of ultrasound treatment. The prognosis of patients in Cluster 2 was better than that in Cluster 1, and a considerable variation was observed in the immune microenvironment of Cluster 1 and Cluster 2. Lasso analysis finally obtained an 8-gene risk model (GASK1A, LPO, LTK, PRRT4, UGT3A2, BLOCK1S1, G6PD, and UNC93B1). The model acted as an independent risk factor for the patients’ prognosis, and it showed good robustness in different datasets. Considerable variations were observed in the abundance of immune cell infiltration, genome mutation, pathway enrichment score, and chemotherapeutic drug resistance between the low and high-risk groups in accordance with the risk score (RS). Additionally, model-based RSs in the immunotherapy cohort were significantly different between complete remission (CR) and other response groups. Conclusion. The prognosis of people with LAML can be predicted using the 8-gene signature.

show abstract

“…Additionally, research on innovative multifunctional nanosystems with the combination of imaging and therapy has become a hotspot. Magnetic resonance imaging (MRI), nuclear medicine imaging (NMI), and ultrasound (US) techniques have been extensively used [ 11 , 12 , 13 , 14 ] in the context of medical imaging modalities (e.g., computed tomography (CT)). To be specific, MRI is a popular imaging technology due to its high-resolution morphological capabilities, non-invasiveness, and lack of risk of radiation damage [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

pH-Responsive Drug Delivery and Imaging Study of Hybrid Mesoporous Silica Nanoparticles

Guo²,

Qi³

et al. 2022

Molecules

View full text Add to dashboard Cite

A system of pH-responsive and imaging nanocarriers was developed using mesoporous silica nanoparticles (MSNs), in which gadolinium (Gd) was doped through in situ doping (Gd2O3@MSN). Sodium alginate (SA) was attached to the surfaces of the amino groups of MSNs (NH2-Gd2O3@MSN) through the electrostatic adsorption between the amino groups and the carboxyl groups with the formation of hybrid SA-Gd2O3@MSN nanoparticles (NPs). The SA-coated NPs were spherical or near-spherical in shape with an average size of nearly 83.2 ± 8.7 nm. The in vitro drug release experiments of a model rhodamine B (RhB) cargo were performed at different pH values. The result confirmed the pH-responsiveness of the nanocarriers. The results of the cytotoxicity studies indicated that the SA-Gd2O3@MSN NPs were not cytotoxic by themselves. The results of the in vivo safety evaluation and the hemolysis assay confirmed that the system is highly biocompatible. It is noteworthy that the T1 contrast of the system was significantly enhanced by the Gd, as indicated by the result of the MR imaging. This study confirms that the synthesized hybrid nanosystem is promising for pH-responsive drug delivery and MR imaging for cancer diagnosis and treatment.

show abstract

Ultrasound-guided Brachytherapy for Cervix Cancer

Cited by 16 publications

References 43 publications

Ultrasound-Guided Brachytherapy for Cervical Cancer - A Tool for Quality Improvement in Brachytherapy?

Ultrasound-Guided Brachytherapy for Cervical Cancer - A Tool for Quality Improvement in Brachytherapy?

Identification of Ultrasound-Sensitive Prognostic Markers of LAML and Construction of Prognostic Risk Model Based on WGCNA

pH-Responsive Drug Delivery and Imaging Study of Hybrid Mesoporous Silica Nanoparticles

Contact Info

Product

Resources

About